The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).
 
Mark D. Pegram
Employment - Rain Oncology (I)
Leadership - Elucida Oncology
Stock and Other Ownership Interests - Lilly; Rain Therapeutics
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Novartis; Pfizer; Roche/Genentech; Stemline Therapeutics
Expert Testimony - Genentech
 
Carmen Calfa
No Relationships to Disclose
 
Christopher Chen
Consulting or Advisory Role - Boxer Capital; Globepoint Global
Research Funding - ADC Therapeutics (Inst); Gilead Sciences (Inst); Kinnate Biopharma (Inst); Mersana (Inst); ORIC Pharmaceuticals (Inst); Palleon Pharmaceuticals (Inst); Pionyr Therapeutics (Inst); Rain Oncology (Inst); Seagen (Inst); Takeda (Inst)
 
Alfonso Cortés Salgado
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Pfizer
Speakers' Bureau - Accord Healthcare; AstraZeneca Spain; Eisai; GlaxoSmithKline; MSD; Pfizer
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Pfizer
Other Relationship - ONCARE Madrid
 
Arielle Lutterman Heeke
Consulting or Advisory Role - Amgen; AstraZeneca; Caris Life Sciences; Daiichi Sankyo/Astra Zeneca; Genome Insight; Menarini; Pfizer
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca
 
Irene Kang
Honoraria - Gilead Sciences
Consulting or Advisory Role - Caris Life Sciences; Daiichi Sankyo/Astra Zeneca; Pfizer
Travel, Accommodations, Expenses - Gilead Sciences
 
Barbara Pistilli
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Myriad Genetics; Novartis; PIERRE FABRE; Puma Biotechnology
Research Funding - AstraZeneca (Inst); DAIICHI-SANKYO (Inst); Gilead Sciences (Inst); Merus (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; MSD Oncology; Novartis; Pfizer; Pierre Fabre
 
Paula R Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Honoraria - Dava Oncology; Frontiers Media; OncLive/MJH Life Sciences; SABCS
Consulting or Advisory Role - Abbvie; Bolt Biotherapeutics; Caris Life Sciences; HERON; Immunonet BioSciences; Juniper Pharmaceuticals; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer; Pfizer; Puma Biotechnology; Sirtex Medical
Speakers' Bureau - Genentech/Roche
Research Funding - Advanced Cancer Therapeutics (Inst); Bolt Biotherapeutics (Inst); Byondis (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Carisma Therapeutics (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Orum Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); SEAGEN (Inst); SEAGEN (Inst); SEAGEN (Inst)
Patents, Royalties, Other Intellectual Property - Patent application; United States Patent no. 8,486,413.; United States Patent no. 8,501,417; United States Patent no. 9,023,362; United States Patent no. 9,745,377
(OPTIONAL) Uncompensated Relationships - Jazz Pharmaceuticals; Pfizer; SEAGEN
 
Hope S. Rugo
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Mylan; Napo Pharmaceuticals; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Taiho Oncology (Inst); Veru (Inst)
 
Cristina Saura
Honoraria - AstraZéneca; Daiichi Sankyo/Astra Zeneca; Eisai Europe,Ltd; Phillips Health Works; Puma Biotechnology; Roche Pharma AG; Seagen; Solti; Zymeworks
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; MediTech; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; SeaGen; Synthon; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Novartis; Pfizer; Puma Biotechnology; Roche
Other Relationship - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd'
 
Cecile Vicier
Honoraria - seagen
Consulting or Advisory Role - BMSi; Daiichi Sankyo/Astra Zeneca; Novartis (Inst); Owkin; Pfizer
Research Funding - BMS Norway (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Novartis; Pfizer
 
Cecelia Pearson
Employment - Bolt Biotherapeutics
 
Milan Mangeshkar
Employment - Bolt Biotherapeutics
 
Tai Yu
Employment - Bolt Biotherapeutics
 
Michael N. Alonso
Employment - Bolt Biotherapeutics
 
Dawn E. Colburn
Employment - Bolt Biotherapeutics
 
Edith A. Perez
Employment - Bolt Biotherapeutics
Leadership - Bolt Biotherapeutics
 
Joshua Z. Drago
Honoraria - Intellisphere
Consulting or Advisory Role - AmMax Bio; AstraZeneca; GenagonTherapeutics; Launchpad Therapeutics; NuProbe
Research Funding - AstraZeneca (Inst); Bolt Biotherapeutics (Inst)